NGM Biopharmaceuticals, Inc. (NGM)
Stock Price:
$17.46 USD
0.02 (0.11%)
Updated Oct 28, 2020 12:20 PM EDT - Market open
Key Info
| Market Cap |
1.20B |
| Revenue (ttm) |
96.77M |
| Net Income (ttm) |
-71.59M |
| Shares Out |
68.83M |
| EPS (ttm) |
-1.07 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$17.46 |
| Previous Close |
$17.44 |
| Change ($) |
0.02 |
| Change (%) |
0.11% |
| Day's Open |
17.16 |
| Day's Range |
16.73 - 17.50 |
| Day's Volume |
69,527 |
| 52-Week Range |
9.25 - 23.95 |
More Stats
| Market Cap |
1.20B |
| Enterprise Value |
887.76M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
68.83M |
| Float |
16.50M |
| EPS (basic) |
-1.08 |
| EPS (diluted) |
-1.07 |
| FCF / Share |
-0.91 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.06M |
| Short Ratio |
25.67 |
| Short % of Float |
24.63% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
12.42 |
| PB Ratio |
3.89 |
| Revenue |
96.77M |
| Operating Income |
-173.26M |
| Net Income |
-71.59M |
| Free Cash Flow |
-62.25M |
| Net Cash |
313.97M |
| Net Cash / Share |
4.56 |
| Gross Margin |
42.66% |
| Operating Margin |
-179.05% |
| Profit Margin |
n/a |
| FCF Margin |
-64.32% |
| ROA |
-12.85% |
| ROE |
-22.12% |
| ROIC |
-104.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (9)
| Buy |
9 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$30.78*
(76.29% upside)
Low
26.0
Current: $17.46
High
39.0
Target: 30.78
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -153 | -113 | -94.57 |
| Net Income | -42.80 | -0.49 | -14.16 |
| Shares Outstanding | 50.30 | 6.38 | 5.96 |
| Earnings Per Share | -0.85 | -0.08 | -2.37 |
| Operating Cash Flow | -41.17 | -7.60 | -17.41 |
| Capital Expenditures | -3.49 | -5.84 | -6.42 |
| Free Cash Flow | -44.66 | -13.44 | -23.84 |
| Cash & Equivalents | 346 | 209 | 176 |
| Net Cash / Debt | 346 | 209 | 176 |
| Assets | 380 | 246 | 249 |
| Liabilities | 49.68 | 59.41 | 75.05 |
| Book Value | 331 | -108 | -121 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
NGM Biopharmaceuticals, Inc. |
| Country |
United States |
| Employees |
186 |
| CEO |
David J. Woodhouse |
Stock Information
| Ticker Symbol |
NGM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NGM |
| IPO Date |
April 4, 2019 |
Description
NGM Biopharmaceuticals, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.